Login to Your Account

Frequency locks on $32M series A for hearing loss drug

By Michael Fitzhugh
Staff Writer

Tuesday, April 11, 2017

Frequency Therapeutics Inc., a company working to develop a progenitor cell-activating hearing restoration therapy, has closed a $32 million series A financing led by Cobro Ventures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription